Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 636
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
1.
Nat Immunol ; 19(8): 859-870, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-30013146

RESUMEN

IgE is an ancient and conserved immunoglobulin isotype with potent immunological function. Nevertheless, the regulation of IgE responses remains an enigma, and evidence of a role for IgE in host defense is limited. Here we report that topical exposure to a common environmental DNA-damaging xenobiotic initiated stress surveillance by γδTCR+ intraepithelial lymphocytes that resulted in class switching to IgE in B cells and the accumulation of autoreactive IgE. High-throughput antibody sequencing revealed that γδ T cells shaped the IgE repertoire by supporting specific variable-diversity-joining (VDJ) rearrangements with unique characteristics of the complementarity-determining region CDRH3. This endogenous IgE response, via the IgE receptor FcεRI, provided protection against epithelial carcinogenesis, and expression of the gene encoding FcεRI in human squamous-cell carcinoma correlated with good disease prognosis. These data indicate a joint role for immunosurveillance by T cells and by B cells in epithelial tissues and suggest that IgE is part of the host defense against epithelial damage and tumor development.


Asunto(s)
Linfocitos B/fisiología , Carcinoma de Células Escamosas/inmunología , Células Epiteliales/fisiología , Inmunoglobulina E/metabolismo , Linfocitos Intraepiteliales/fisiología , Neoplasias Experimentales/inmunología , Receptores de Antígenos de Linfocitos T gamma-delta/metabolismo , Receptores de IgE/metabolismo , Animales , Antracenos/toxicidad , Carcinoma de Células Escamosas/diagnóstico , Muerte Celular , Células Cultivadas , Regiones Determinantes de Complementariedad/genética , Daño del ADN , Femenino , Secuenciación de Nucleótidos de Alto Rendimiento , Cambio de Clase de Inmunoglobulina , Inmunoglobulina E/genética , Vigilancia Inmunológica , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Neoplasias Experimentales/inducido químicamente , Piperidinas/toxicidad , Pronóstico , Receptores de Antígenos de Linfocitos T gamma-delta/genética
2.
J Cell Mol Med ; 28(4): e18118, 2024 02.
Artículo en Inglés | MEDLINE | ID: mdl-38332529

RESUMEN

Opioids can be used for medical and non-medical purposes. Chronic pain such as cancer, as well as the frequent use of such drugs in places such as operating rooms and intensive care units, and in non-medical areas like drug abuse the effects and side effects of these drugs need to be examined in more detail. For this purpose, the effects of fentanyl and remifentanil drugs on neuroinflammation, oxidative stress and cholinesterase metabolism were investigated. Neuron cells (CRL-10742) were used for the evaluation of the toxicity of fentanyl and remifentanil. MTT, PON1 activity and total thiol levels for its effect on oxidative stress, AChE and BChE activities for its effect on the cholinergic system, and TNF, IL-8 and IL-10 gene levels for its neuroinflammation effect were determined. The highest neurotoxic dose of fentanyl and remifentanil was determined as 10 µg/mL. It was observed that the rate of neuron cells in this dose has decreased by up to 61.80% and 56.89%, respectively. The IL-8 gene expression level in both opioids was down-regulated while IL 10 gene level was up-regulated in a dose-dependent manner compared to the control. In our results, the TNF gene expression level differs between the two opioids. In the fentanyl group, it was seen to be up-regulated in a dose-dependent manner compared to the control. Fentanyl and remifentanil showed an inhibitory effect against PON1, while remifentanil showed an increase in total thiol levels. PON1, BChE and total thiol activities showed similarity with MTT.


Asunto(s)
Dolor Crónico , Fentanilo , Humanos , Fentanilo/toxicidad , Remifentanilo/farmacología , Piperidinas/toxicidad , Interleucina-8 , Enfermedades Neuroinflamatorias , Analgésicos Opioides/toxicidad , Estrés Oxidativo , Neuronas , Dolor Crónico/inducido químicamente , Compuestos de Sulfhidrilo , Arildialquilfosfatasa
3.
Circulation ; 142(25): 2443-2455, 2020 12 22.
Artículo en Inglés | MEDLINE | ID: mdl-33092403

RESUMEN

BACKGROUND: Ibrutinib is a Bruton tyrosine kinase inhibitor with remarkable efficacy against B-cell cancers. Ibrutinib also increases the risk of atrial fibrillation (AF), which remains poorly understood. METHODS: We performed electrophysiology studies on mice treated with ibrutinib to assess inducibility of AF. Chemoproteomic analysis of cardiac lysates identified candidate ibrutinib targets, which were further evaluated in genetic mouse models and additional pharmacological experiments. The pharmacovigilance database, VigiBase, was queried to determine whether drug inhibition of an identified candidate kinase was associated with increased reporting of AF. RESULTS: We demonstrate that treatment of mice with ibrutinib for 4 weeks results in inducible AF, left atrial enlargement, myocardial fibrosis, and inflammation. This effect was reproduced in mice lacking Bruton tyrosine kinase, but not in mice treated with 4 weeks of acalabrutinib, a more specific Bruton tyrosine kinase inhibitor, demonstrating that AF is an off-target side effect. Chemoproteomic profiling identified a short list of candidate kinases that was narrowed by additional experimentation leaving CSK (C-terminal Src kinase) as the strongest candidate for ibrutinib-induced AF. Cardiac-specific Csk knockout in mice led to increased AF, left atrial enlargement, fibrosis, and inflammation, phenocopying ibrutinib treatment. Disproportionality analyses in VigiBase confirmed increased reporting of AF associated with kinase inhibitors blocking Csk versus non-Csk inhibitors, with a reporting odds ratio of 8.0 (95% CI, 7.3-8.7; P<0.0001). CONCLUSIONS: These data identify Csk inhibition as the mechanism through which ibrutinib leads to AF. Registration: URL: https://ww.clinicaltrials.gov; Unique identifier: NCT03530215.


Asunto(s)
Adenina/análogos & derivados , Antineoplásicos/toxicidad , Fibrilación Atrial/inducido químicamente , Función del Atrio Izquierdo/efectos de los fármacos , Proteína Tirosina Quinasa CSK/antagonistas & inhibidores , Atrios Cardíacos/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Piperidinas/toxicidad , Inhibidores de Proteínas Quinasas/toxicidad , Potenciales de Acción/efectos de los fármacos , Adenina/toxicidad , Agammaglobulinemia Tirosina Quinasa/deficiencia , Agammaglobulinemia Tirosina Quinasa/genética , Animales , Fibrilación Atrial/enzimología , Fibrilación Atrial/fisiopatología , Proteína Tirosina Quinasa CSK/genética , Proteína Tirosina Quinasa CSK/metabolismo , Bases de Datos Genéticas , Atrios Cardíacos/enzimología , Atrios Cardíacos/fisiopatología , Humanos , Ratones de la Cepa 129 , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Ratones Noqueados , Medición de Riesgo , Factores de Riesgo
4.
Ann Neurol ; 88(4): 771-784, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32583883

RESUMEN

OBJECTIVE: Calcitonin gene-related peptide (CGRP) pathway inhibitors are emerging treatments for migraine. CGRP-mediated vasodilation is, however, a critical rescue mechanism in ischemia. We, therefore, investigated whether gepants, small molecule CGRP receptor antagonists, worsen cerebral ischemia. METHODS: Middle cerebral artery was occluded for 12 to 60 minutes in mice. We compared infarct risk and volumes, collateral flow, and neurological deficits after pretreatment with olcegepant (single or 10 daily doses of 0.1-1mg/kg) or rimegepant (single doses of 10-100mg/kg) versus vehicle. We also determined their potency on CGRP-induced relaxations in mouse and human vessels, in vitro. RESULTS: Olcegepant (1mg/kg, single dose) increased infarct risk after 12- to 20-minute occlusions mimicking transient ischemic attacks (14/19 vs 6/18 with vehicle, relative risk = 2.21, p < 0.022), and doubled infarct volumes (p < 0.001) and worsened neurological deficits (median score = 9 vs 5 with vehicle, p = 0.008) after 60-minute occlusion. Ten daily doses of 0.1 to 1mg/kg olcegepant yielded similar results. Rimegepant 10mg/kg increased infarct volumes by 60% after 20-minute ischemia (p = 0.03); 100mg/kg caused 75% mortality after 60-minute occlusion. In familial hemiplegic migraine type 1 mice, olcegepant 1mg/kg increased infarct size after 30-minute occlusion (1.6-fold, p = 0.017). Both gepants consistently diminished collateral flow and reduced reperfusion success. Olcegepant was 10-fold more potent than rimegepant on CGRP-induced relaxations in mouse aorta. INTERPRETATION: Gepants worsened ischemic stroke in mice via collateral dysfunction. CGRP pathway blockers might thus aggravate coincidental cerebral ischemic events. The cerebrovascular safety of these agents must therefore be better delineated, especially in patients at increased risk of ischemic events or on prophylactic CGRP inhibition. ANN NEUROL 2020;88:771-784.


Asunto(s)
Arterias/efectos de los fármacos , Isquemia Encefálica , Antagonistas del Receptor Peptídico Relacionado con el Gen de la Calcitonina/toxicidad , Vasodilatación/efectos de los fármacos , Animales , Péptido Relacionado con Gen de Calcitonina/metabolismo , Dipéptidos/toxicidad , Humanos , Ratones , Piperazinas , Piperidinas/toxicidad , Piridinas/toxicidad , Quinazolinas/toxicidad
5.
Toxicol Appl Pharmacol ; 433: 115781, 2021 12 15.
Artículo en Inglés | MEDLINE | ID: mdl-34737147

RESUMEN

The cardiac embryonic stem cell test (ESTc) is an in vitro embryotoxicity screen which uses cardiomyocyte formation as the main differentiation route. Studies are ongoing into whether an improved specification of the biological domain can broaden the applicability of the test, e.g. to discriminate between structurally similar chemicals by measuring expression of dedicated gene transcript biomarkers. We explored this with two chemical classes: morpholines (tridemorph; fenpropimorph) and piperidines (fenpropidin; spiroxamine). These compounds cause embryotoxicity in rat such as cleft palate. This malformation can be linked to interference with retinoic acid balance, neural crest (NC) cell migration, or cholesterol biosynthesis. Also neural differentiation within the ESTc was explored in relation to these compounds. Gene transcript expression of related biomarkers were measured at low and high concentrations on differentiation day 4 (DD4) and DD10. All compounds showed stimulating effects on the cholesterol biosynthesis related marker Msmo1 after 24 h exposure and tridemorph showed inhibition of Cyp26a1 which codes for one of the enzymes that metabolises retinoic acid. A longer exposure duration enhanced expression levels for differentiation markers for cardiomyocytes (Nkx2-5; Myh6) and neural cells (Tubb3) on DD10. This readout gave additional mechanistic insight which enabled previously unavailable in vitro discrimination between the compounds, showing the practical utility of specifying the biological domain of the ESTc.


Asunto(s)
Diferenciación Celular/efectos de los fármacos , Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Morfolinas/toxicidad , Células Madre Embrionarias de Ratones/efectos de los fármacos , Miocitos Cardíacos/efectos de los fármacos , Piperidinas/toxicidad , Pruebas de Toxicidad , Animales , Células Cultivadas , Redes Reguladoras de Genes , Proteína Homeótica Nkx-2.5/genética , Proteína Homeótica Nkx-2.5/metabolismo , Ratones , Oxigenasas de Función Mixta/genética , Oxigenasas de Función Mixta/metabolismo , Células Madre Embrionarias de Ratones/metabolismo , Células Madre Embrionarias de Ratones/patología , Miocitos Cardíacos/metabolismo , Miocitos Cardíacos/patología , Cadenas Pesadas de Miosina/genética , Cadenas Pesadas de Miosina/metabolismo , Ácido Retinoico 4-Hidroxilasa/genética , Ácido Retinoico 4-Hidroxilasa/metabolismo , Medición de Riesgo , Compuestos de Espiro/toxicidad , Factores de Tiempo , Tubulina (Proteína)/genética , Tubulina (Proteína)/metabolismo
6.
Bioorg Chem ; 115: 105196, 2021 10.
Artículo en Inglés | MEDLINE | ID: mdl-34333425

RESUMEN

So far, there is still no specific drug against COVID-19. Taking compound 1 with anti-EBOV activity as the lead, fifty-four 12N-substituted aloperine derivatives were synthesized and evaluated for the anti-SARS-CoV-2 activities using pseudotyped virus model. Among them, 8a exhibited the most potential effects against both pseudotyped and authentic SARS-CoV-2, as well as SARS-CoV and MERS-CoV, indicating a broad-spectrum anti-coronavirus profile. The mechanism study disclosed that 8a might block a late stage of viral entry, mainly via inhibiting host cathepsin B activity rather than directly targeting cathepsin B protein. Also, 8a could significantly reduce the release of multiple inflammatory cytokines in a time- and dose-dependent manner, such as IL-6, IL-1ß, IL-8 and MCP-1, the major contributors to cytokine storm. Therefore, 8a is a promising agent with the advantages of broad-spectrum anti-coronavirus and anti-cytokine effects, thus worthy of further investigation.


Asunto(s)
Antivirales/farmacología , Piperidinas/farmacología , Quinolizidinas/farmacología , SARS-CoV-2/efectos de los fármacos , Internalización del Virus/efectos de los fármacos , Animales , Antivirales/síntesis química , Antivirales/farmacocinética , Antivirales/toxicidad , Catepsina B/antagonistas & inhibidores , Chlorocebus aethiops , Citocinas/metabolismo , Células HEK293 , Humanos , Masculino , Ratones , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Piperidinas/síntesis química , Piperidinas/farmacocinética , Piperidinas/toxicidad , Quinolizidinas/síntesis química , Quinolizidinas/farmacocinética , Quinolizidinas/toxicidad , Ratas Sprague-Dawley , Relación Estructura-Actividad , Células Vero
7.
Ecotoxicology ; 30(1): 80-90, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33222056

RESUMEN

QYM201 is a 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibiting herbicide recently registered in China for controlling grass and broadleaf weeds in wheat. It is a novel herbicide, and its potential harm to soil ecosystems has not yet been reported. This study investigates the influence of QYM201 on soil enzyme activity and microorganism quantities in two different soils at concentrations of 0.1, 1, and 5 mg kg-1 soil. Results indicate that QYM201 initially inhibited soil protease, urease, and sucrase activity and this effect increased with concentration. During the later stages of incubation, inhibitory effects gradually weakened and by the end of the experiment (45 days), enzyme activity was restored to control levels. Catalase activity was stimulated by QYM201, with significant differences observed between the QYM201-treated groups and the control at the onset of exposure. This stimulation effect decreased during the later stages of the experiment. However, catalase activity was still significantly higher at the end of the experiment compared to the control. The effects of QYM201 on soil microorganisms differed. Initially, bacteria and actinomycetes quantities were decreased by QYM201 (10 days). As the incubation progressed, microorganism quantities in the lower concentration groups (0.1 and 1 mg kg-1 soil) were restored to control levels, while those of the high concentration group (5 mg kg-1 soil) did not fully recover. QYM201 did not significantly impact the quantity of fungi. The half-life and degradation rate constant (k) of QYM201 for the two studied soil types were 23.1 days and 16.1 days, and 0.030 and 0.043 day-1, respectively.


Asunto(s)
Inhibidores Enzimáticos/toxicidad , Herbicidas , Piperidinas/toxicidad , Pirazoles/toxicidad , Contaminantes del Suelo , 4-Hidroxifenilpiruvato Dioxigenasa/antagonistas & inhibidores , China , Ecosistema , Herbicidas/análisis , Herbicidas/toxicidad , Suelo , Microbiología del Suelo , Contaminantes del Suelo/análisis , Contaminantes del Suelo/toxicidad
8.
Phytother Res ; 35(2): 680-700, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-32929825

RESUMEN

Medicinal plants have been used for years as a source of food, spices, and, in traditional medicine, as a remedy to numerous diseases. Piper nigrum, belonging to the family Piperaceae is one of the most widely used spices all over the world. It has a distinct sharp flavor attributed to the presence of the phytochemical, piperine. Apart from its use as a spice, P. nigrum is frequently used for medicinal, preservation, and perfumery purposes. Black pepper contains 2-7.4% of piperine, varying in content is associated with the pepper plant. Piperine displays numerous pharmacological effects such as antiproliferative, antitumor, antiangiogenesis, antioxidant, antidiabetic, anti-obesity, cardioprotective, antimicrobial, antiaging, and immunomodulatory effects in various in vitro and in vivo experimental trials. Furthermore, piperine has also been documented for its hepatoprotective, anti-allergic, anti-inflammatory, and neuroprotective properties. This review highlights and discusses the medicinal and health-promoting effects of piperine, along with possible mechanisms of its action in health promotion and disease prevention. In addition, the present review summarizes the recent literature related to piperine as a therapeutic agent against several diseases.


Asunto(s)
Alcaloides , Benzodioxoles , Piperidinas , Alcamidas Poliinsaturadas , Alcaloides/farmacocinética , Alcaloides/uso terapéutico , Alcaloides/toxicidad , Animales , Benzodioxoles/farmacocinética , Benzodioxoles/uso terapéutico , Benzodioxoles/toxicidad , Quimioterapia Combinada , Humanos , Piperidinas/farmacocinética , Piperidinas/uso terapéutico , Piperidinas/toxicidad , Alcamidas Poliinsaturadas/farmacocinética , Alcamidas Poliinsaturadas/uso terapéutico , Alcamidas Poliinsaturadas/toxicidad
9.
Ter Arkh ; 93(7): 770-777, 2021 Jul 23.
Artículo en Ruso | MEDLINE | ID: mdl-36286727

RESUMEN

BACKGROUND: Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current approaches have greatly improved patients outcomes, but relapse is inevitable. In phase IIIII clinical trials, ibrutinib has shown significant activity in patients with relapsed or refractory (R/R) MCL. AIM: To assess efficacy and toxicity of ibrutinib monotherapy in patients with R/R MCL in routine practice outside of clinical trials. MATERIALS AND METHODS: The study enrolled patients with confirmed R/R MCL who had received at least one line of previous chemotherapy. ECOG 24, cytopenia, infectious complications, hemorrhagic syndrome were not exclusion criteria. Patients received daily oral ibrutinib 560 mg until progression or unacceptable toxicity. RESULTS: From May 2015 to September 2020 ibrutinib therapy was started in 106 patients with R/R MCL in 16 regions of Russia. The median age was 66 years; ECOG2 18%, blastoid variant (or Ki6740% or WBC50109/l) 43%. The median number of previous treatment lines was 2 (111). The ORR was 78.4% (CRR 27.4%). The median PFS was 13.6 months and OS 23.2 months. In the blastoid group the median PFS was 4.4 months vs 36.5 months in the alternative group (p0.001), the median OS 9.0 vs 41.0 (p=0.001). The median OS of patients after progression on ibrutinib was 3.2 months. The common complications are hemorrhages (63%), diarrhea (62%), myalgia and muscle cramps (60%), infections (31%), skin and nail toxicity 15%, arrhythmia 8%. None of recipients had to completely discontinue ibrutinib therapy due to complications. CONCLUSION: Ibrutinib is effective and well tolerated in routine practice of R/R MCL treatment and our results are consistent with international clinical trials. The favorable toxicity profile and the high response rate made it possible to prescribe ibrutinib in severe somatic status, cytopenia, and even in the presence of infectious complications.


Asunto(s)
Adenina , Linfoma de Células del Manto , Recurrencia Local de Neoplasia , Piperidinas , Anciano , Humanos , Linfoma de Células del Manto/tratamiento farmacológico , Linfoma de Células del Manto/patología , Recurrencia Local de Neoplasia/tratamiento farmacológico , Piperidinas/uso terapéutico , Piperidinas/toxicidad , Adenina/análogos & derivados , Adenina/uso terapéutico , Adenina/toxicidad , Federación de Rusia , Ensayos Clínicos como Asunto
10.
Am J Physiol Renal Physiol ; 319(4): F563-F570, 2020 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-32799675

RESUMEN

Acute kidney injury (AKI) frequently complicates major surgery and can be associated with hypertension and progress to chronic kidney disease, but reports on blood pressure normalization in AKI are conflicting. In the present study, we investigated the effects of an angiotensin-converting enzyme inhibitor, enalapril, and a soluble epoxide hydrolase inhibitor, 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea (TPPU), on renal inflammation, fibrosis, and glomerulosclerosis in a mouse model of ischemia-reperfusion injury (IRI)-induced AKI. Male CD1 mice underwent unilateral IRI for 35 min. Blood pressure was measured by tail cuff, and mesangial matrix expansion was quantified on methenamine silver-stained sections. Renal perfusion was assessed by functional MRI in vehicle- and TPPU-treated mice. Immunohistochemistry was performed to study the severity of AKI and inflammation. Leukocyte subsets were analyzed by flow cytometry, and proinflammatory cytokines were analyzed by quantitative PCR. Plasma and tissue levels of TPPU and lipid mediators were analyzed by liquid chromatography mass spectrometry. IRI resulted in a blood pressure increase of 20 mmHg in the vehicle-treated group. TPPU and enalapril normalized blood pressure and reduced mesangial matrix expansion. However, inflammation and progressive renal fibrosis were severe in all groups. TPPU further reduced renal perfusion on days 1 and 14. In conclusion, early antihypertensive treatment worsened renal outcome after AKI by further reducing renal perfusion despite reduced glomerulosclerosis.


Asunto(s)
Lesión Renal Aguda/tratamiento farmacológico , Antihipertensivos/farmacología , Presión Sanguínea/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Glomerulonefritis/prevención & control , Hipertensión/tratamiento farmacológico , Compuestos de Fenilurea/farmacología , Piperidinas/farmacología , Daño por Reperfusión/tratamiento farmacológico , Lesión Renal Aguda/etiología , Lesión Renal Aguda/patología , Lesión Renal Aguda/fisiopatología , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Animales , Antihipertensivos/toxicidad , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Enalapril/farmacología , Inhibidores Enzimáticos/toxicidad , Epóxido Hidrolasas/antagonistas & inhibidores , Fibrosis , Mesangio Glomerular/efectos de los fármacos , Mesangio Glomerular/patología , Mesangio Glomerular/fisiopatología , Glomerulonefritis/etiología , Glomerulonefritis/patología , Glomerulonefritis/fisiopatología , Hipertensión/etiología , Hipertensión/fisiopatología , Masculino , Ratones , Compuestos de Fenilurea/toxicidad , Piperidinas/toxicidad , Daño por Reperfusión/complicaciones , Daño por Reperfusión/fisiopatología
11.
Mol Carcinog ; 59(11): 1302-1316, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-33006223

RESUMEN

Oral squamous cell carcinoma (OSCC) is a common malignant tumor of the head and neck. However, the molecular mechanism underlying its development and progression is yet unclear. Genes that are differentially expressed, that is, differentially expressed genes (DEGs), between normal and diseased tissues are believed to be involved in disease development and progression. To identify the DEGs in OSCC and explore their role in occurrence and progression, we established a Chinese hamster OSCC model, determined the DEG, screened the identified DEGs, and performed Gene Ontology (GO) and KEGG enrichment analyses. A protein-protein interaction (PPI) network was generated to screen potential candidate genes. We then analyzed the expression, tumor stage and prognosis of candidate genes using the Gene Expression Profiling Interactive Analysis (GEPIA) database. Finally, we verified the candidate DEGs by quantitative real-time PCR and Gene Expression Omnibus analysis. The results showed 194 significantly DEGs, 140 enriched GO terms, and 8 KEGG pathways, which suggested that OSCC was closely related to the immune system, cell migration, and extracellular matrix. GEPIA and PPI network analysis revealed that SPP1, TNC, and ACTA1 were significantly related to tumor staging; SPP1, tissue inhibitors of matrix metallopeptidases (MMPs) 1 (TIMP1), and ACTA1 were closely related to prognosis. The scores for the top five highest degree genes were close, and the TIMP1/MMP9 axis appeared to be at the center of the PPI network, indicating that expression changes in the TIMP1/MMP9 axis and related genes may be involved in tumor invasion and metastasis. These findings provide novel insights into the mechanism of oral cancer.


Asunto(s)
Antracenos/toxicidad , Biomarcadores de Tumor/metabolismo , Carcinoma de Células Escamosas/patología , Biología Computacional/métodos , Modelos Animales de Enfermedad , Metaloproteinasa 9 de la Matriz/metabolismo , Neoplasias de la Boca/patología , Piperidinas/toxicidad , Inhibidor Tisular de Metaloproteinasa-1/metabolismo , Animales , Apoptosis , Biomarcadores de Tumor/genética , Carcinoma de Células Escamosas/inducido químicamente , Carcinoma de Células Escamosas/metabolismo , Proliferación Celular , Cricetinae , Cricetulus , Regulación Neoplásica de la Expresión Génica , Humanos , Masculino , Metaloproteinasa 9 de la Matriz/genética , Ratones , Neoplasias de la Boca/inducido químicamente , Neoplasias de la Boca/metabolismo , Pronóstico , Inhibidor Tisular de Metaloproteinasa-1/genética , Células Tumorales Cultivadas
12.
Cephalalgia ; 40(9): 903-912, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32580575

RESUMEN

BACKGROUND: Medication overuse is a significant issue that complicates the treatment of headache disorders. The most effective medications for the acute treatment of migraine all have the capacity to induce medication overuse headache (MOH). Novel acute migraine-specific treatments are being developed. However, because the mechanism(s) underlying medication overuse headache are not well understood, it is difficult to predict whether any particular acute medication will induce MOH in susceptible individuals. LY573144 (lasmiditan), a 5-HT1F receptor agonist, has recently been shown to be effective in the acute treatment of migraine in phase 3 trials. The aim of this study is to determine whether frequent administration of lasmiditan induces behaviors consistent with MOH in a pre-clinical rat model. METHODS: Sprague Dawley rats were administered six doses of lasmiditan (10 mg/kg), sumatriptan (10 mg/kg), or sterile water orally over 2 weeks and cutaneous allodynia was evaluated regularly in the periorbital and hindpaw regions using von Frey filaments. Testing continued until mechanosensitivity returned to baseline levels. Rats were then submitted to bright light stress (BLS) or nitric oxide (NO) donor administration and were again evaluated for cutaneous allodynia in the periorbital and hindpaw regions hourly for 5 hours. RESULTS: Both lasmiditan and sumatriptan exhibited comparable levels of drug-induced cutaneous allodynia in both the periorbital and hindpaw regions, which resolved after cessation of drug administration. Both lasmiditan and sumatriptan pre-treatment resulted in cutaneous allodynia that was evoked by either BLS or NO donor. CONCLUSIONS: In a pre-clinical rat model of MOH, oral lasmiditan, like sumatriptan, induced acute transient cutaneous allodynia in the periorbital and hindpaw regions that after resolution could be re-evoked by putative migraine triggers. These results suggest that lasmiditan has the capacity to induce MOH through persistent latent peripheral and central sensitization mechanisms.


Asunto(s)
Analgésicos/toxicidad , Benzamidas/toxicidad , Cefaleas Secundarias/inducido químicamente , Hiperalgesia/inducido químicamente , Piperidinas/toxicidad , Piridinas/toxicidad , Agonistas de Receptores de Serotonina/toxicidad , Animales , Sensibilización del Sistema Nervioso Central/efectos de los fármacos , Modelos Animales de Enfermedad , Ratas , Ratas Sprague-Dawley , Sumatriptán/toxicidad
13.
Cardiovasc Drugs Ther ; 34(1): 15-23, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-32062793

RESUMEN

PURPOSE: Drugs inhibiting the platelet P2Y12 receptor, such as clopidogrel and prasugrel, are potent antithrombotic agents and are widely used in cardiovascular disease. However, the adverse effects of these drugs have limited their clinical use. For example, clopidogrel resistance occurs in approximately one third of patients, while prasugrel increases the risk of major bleeding. Therefore, new generations of such drugs are of clinical interest. METHODS: In this study, the pharmacodynamics of a new P2Y12 antagonist, CN-218, was compared with that of clopidogrel and prasugrel in rats and mice. The differences between CN-218 and clopidogrel include deuteration of the 7-position methyl carboxylate and the introduction of cinnamate in the 2-position of thiophene. RESULTS: CN-218 had an antiaggregatory efficacy that was at least five times more potent than that of clopidogrel but not as potent as that of prasugrel. It had a significant impact on activated partial thromboplastin time (APTT), whereby the APTT of CN-218-treated rats was approximately 9 s longer than that of the vehicle- or clopidogrel-treated group, while it had no impact on prothrombin time (PT) in rats. CN-218 had a similar potent antithrombotic effect to that of prasugrel and clopidogrel and also reduced the risk of bleeding compared to prasugrel. CONCLUSION: CN-218 may be a promising antithrombotic agent, with potent antiplatelet and significant anticoagulant activity, as well as a lower risk of bleeding compared to clopidogrel and prasugrel.


Asunto(s)
Coagulación Sanguínea/efectos de los fármacos , Plaquetas/efectos de los fármacos , Fibrinolíticos/farmacología , Piperidinas/farmacología , Inhibidores de Agregación Plaquetaria/farmacología , Agregación Plaquetaria/efectos de los fármacos , Antagonistas del Receptor Purinérgico P2Y/farmacología , Receptores Purinérgicos P2Y12/efectos de los fármacos , Tiofenos/farmacología , Trombosis/prevención & control , Animales , Plaquetas/metabolismo , Carragenina , Clopidogrel/farmacología , AMP Cíclico/sangre , Modelos Animales de Enfermedad , Fibrinolíticos/toxicidad , Hemorragia/inducido químicamente , Masculino , Ratones , Piperidinas/toxicidad , Inhibidores de Agregación Plaquetaria/toxicidad , Clorhidrato de Prasugrel/farmacología , Antagonistas del Receptor Purinérgico P2Y/toxicidad , Ratas Wistar , Receptores Purinérgicos P2Y12/sangre , Tiofenos/toxicidad , Trombosis/sangre , Trombosis/inducido químicamente
14.
J Biochem Mol Toxicol ; 34(3): e22441, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31926054

RESUMEN

Inflammation plays a vital role in the process of carcinogenesis and anti-inflammatory properties of phytochemicals are gaining more attention in the chemoprevention of cancer. The present study was designed to evaluate the anti-inflammatory potential of citronellol (CT) on 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinogenesis in rats. The inflammation-associated gene and protein markers were analyzed by immunohistochemistry, reverse transcription polymerase chain reaction, and Western blot techniques. Markers such as nuclear factor-kB (NF-kB), tumor necrosis factor-α, interleukin-6 (IL-6), cyclooxygenase-2, macrophage inflammatory protein-1α, and inducible nitric oxide synthase are upregulated in DMBA-alone-treated mammary tumor tissues. The oral administration of CT (50 mg/kg BW) to DMBA-treated rats significantly downregulated the expression NF-kB and other inflammatory markers, and also increased the level of IL-10 in mammary tissues. The results suggested that the anti-inflammatory potential of CT prevented the incidence of chemical carcinogen-induced mammary cancer in rats.


Asunto(s)
Monoterpenos Acíclicos/farmacología , Neoplasias Mamarias Experimentales , FN-kappa B/metabolismo , Proteínas de Neoplasias/metabolismo , Transducción de Señal/efectos de los fármacos , Animales , Antracenos/toxicidad , Carcinógenos/toxicidad , Femenino , Neoplasias Mamarias Experimentales/inducido químicamente , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Neoplasias Mamarias Experimentales/metabolismo , Neoplasias Mamarias Experimentales/patología , Piperidinas/toxicidad , Ratas , Ratas Sprague-Dawley
15.
Exp Parasitol ; 219: 108018, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33049224

RESUMEN

Nanoencapsulation is the promising approach to enhance the therapeutic potential of a drug. In the present investigation, piperine-loaded nanocapsules (NCs) was prepared and evaluated for antitrypanosomal activity against the parasite Trypanosoma evansi, a causative agent of trypanosomiasis. Piperine, a bioactive compound was selected as an alternative for drugs that have been used for the treatment of the disease from decades to overcome the toxic effects or drug resistance effect. Moreover, piperine has reported to possess therapeutic potential against other Trypanosoma spp. and has also been reported to cause reactive oxygen species (ROS) mediated effect in cancer cells that was the other reason for the selection. To date, piperine and its nanoformulations have not been evaluated for their growth inhibitory effect against T. evansi. Piperine-loaded NCs exhibited more significant antitrypanosomal effect at approximately three-times less IC50 value 5.04 µM as compared to piperine (IC50-14.45 µM). Moreover, increased production of reactive oxygen species observed in the case of piperine-loaded NCs as that of pure piperine in the axenic culture of T. evansi. Furthermore, different concentrations of piperine-loaded NCs showed less cytotoxicity on horse peripheral blood mononuclear cells as liken to pure piperine. In conclusion, our results demonstrated that piperine-loaded NCs induced more generation of ROS that contributed inhibitory effect on the growth of Trypanosoma evansi as compared to pure drug.


Asunto(s)
Alcaloides/farmacología , Benzodioxoles/farmacología , Inhibidores Enzimáticos del Citocromo P-450/farmacología , Piperidinas/farmacología , Alcamidas Poliinsaturadas/farmacología , Trypanosoma/efectos de los fármacos , Alcaloides/toxicidad , Análisis de Varianza , Animales , Benzodioxoles/toxicidad , Inhibidores Enzimáticos del Citocromo P-450/toxicidad , Caballos , Concentración 50 Inhibidora , Leucocitos Mononucleares/efectos de los fármacos , Nanocápsulas , Piperidinas/toxicidad , Alcamidas Poliinsaturadas/toxicidad , Especies Reactivas de Oxígeno/análisis , Especies Reactivas de Oxígeno/metabolismo , Trypanosoma/crecimiento & desarrollo
16.
J Appl Toxicol ; 40(9): 1297-1305, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32285496

RESUMEN

Iloperidone, a second-generation atypical antipsychotic drug, is widely used in the treatment of schizophrenia. However, the side-effects of iloperidone on vascular K+ channels remain to be determined. Therefore, we explored the effect of iloperidone on voltage-dependent K+ (Kv) channels in rabbit coronary arterial smooth muscle cells using the whole-cell patch-clamp technique. Iloperidone inhibited vascular Kv channels in a concentration-dependent manner with a half-maximal inhibitory concentration (IC50 ) of 2.11 ± 0.5 µM and a Hill coefficient of 0.68 ± 0.03. Iloperidone had no effect on the steady-state inactivation kinetics. However, it shifted the steady-state activation curve to the right, indicating that iloperidone inhibited Kv channels by influencing the voltage sensors. Application of 20 repetitive depolarizing pulses (1 and 2 Hz) progressively increased the inhibition of the Kv current in the presence of iloperidone. Furthermore, iloperidone increased the recovery time constant from Kv channel inactivation, suggesting that iloperidone-induced inhibition of Kv channels is use (state)-dependent. Pretreatment with a Kv1.5 inhibitor (diphenyl phosphine oxide 1 [DPO-1]) inhibited the Kv current to a level similar to that with iloperidone alone. However, pretreatment with a Kv2.1 or Kv7.X inhibitor (guangxitoxin or linopirdine) did not affect the inhibitory effect of iloperidone on Kv channels. Therefore, iloperidone directly inhibits Kv channels in a concentration- and use (state)-dependent manner independently of its antagonism of serotonin and dopamine receptors. Furthermore, the primary target of iloperidone is the Kv1.5 subtype.


Asunto(s)
Antipsicóticos/toxicidad , Vasos Coronarios/efectos de los fármacos , Isoxazoles/toxicidad , Potenciales de la Membrana/efectos de los fármacos , Miocitos del Músculo Liso/efectos de los fármacos , Piperidinas/toxicidad , Canales Aniónicos Dependientes del Voltaje/efectos de los fármacos , Antipsicóticos/uso terapéutico , Bloqueadores de los Canales de Potasio , Esquizofrenia/tratamiento farmacológico
17.
Int J Toxicol ; 39(3): 232-240, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32484067

RESUMEN

Zanubrutinib an oral irreversible Bruton's tyrosine kinase (BTK) inhibitor, is under development for the treatment of a variety of B-cell malignancies and has received accelerated approval by the US Food and Drug Administration for treatment of adult patients with mantel cell lymphoma who have received at least one prior therapy. Zanubrutinib moderately inhibited the human ether- à -go-go-related gene channel with half maximal inhibition concentration (IC50) of 9.11 µM and showed neither effects on the cardiovascular system functions in telemetry-implanted dogs nor on the respiratory and central nervous system functions in rats. No toxicologically significant changes were noted in rats and dogs at the systemic exposure ratios (area under the curve ratio between animals and humans at the therapeutic dose) up to 26- and 15-fold for 26-weeks and 39-weeks of treatment, respectively. Zanubrutinib was not genotoxic. Fertility studies showed no abnormal findings in both male and female rats at the systemic exposure ratios of up to 12-fold; embryo-fetal studies showed no fetal lethality or teratogenicity in rabbit or rat fetuses at the systemic exposure ratios of up to 25- and 16-fold, respectively, except for 0.3% to 1.5% of 2 or 3 chambered hearts in rat fetuses; pre- and postnatal developmental toxicity showed no effects in rats at the systemic exposure ratios up to 16-fold except for an increased incidence (26% to 42%) and severity of various ophthalmic lesions in treated groups compared to the concurrent control group (26%). These nonclinical study results suggest that zanubrutinib has a broad safety window and an optimal safety profile while treating patients with advanced cancers.


Asunto(s)
Agammaglobulinemia Tirosina Quinasa/antagonistas & inhibidores , Antineoplásicos/toxicidad , Piperidinas/toxicidad , Inhibidores de Proteínas Quinasas/toxicidad , Pirazoles/toxicidad , Pirimidinas/toxicidad , Animales , Antineoplásicos/farmacología , Perros , Desarrollo Embrionario/efectos de los fármacos , Femenino , Desarrollo Fetal/efectos de los fármacos , Masculino , Piperidinas/farmacología , Inhibidores de Proteínas Quinasas/farmacología , Pirazoles/farmacología , Pirimidinas/farmacología , Conejos , Ratas , Reproducción/efectos de los fármacos , Pruebas de Toxicidad
18.
Int J Mol Sci ; 21(9)2020 Apr 26.
Artículo en Inglés | MEDLINE | ID: mdl-32357484

RESUMEN

While triclosan (TCS) exerts detrimental effects on female reproduction, the effect of TCS-derived toxins on porcine oocytes during in vitro maturation (IVM) is unclear. This study investigated the effects of TCS on mitochondrion-derived reactive oxygen species (ROS) production and apoptosis pathways during porcine oocyte maturation. Porcine oocytes were treated with TCS (1, 10, and 100 µM) and triphenylphosphonium chloride (Mito-TEMPO; 0.1 µM), and matured cumulus oocyte complexes (COCs) were stained with orcein, dichlorofluorescein diacetate (DCF-DA), and Mito-SOX. Proteins and mRNA levels of factors related to cumulus expansion and mitochondrion-mediated apoptosis and antioxidant enzymes were analyzed by western blotting and reverse-transcription polymerase chain reaction (RT-PCR), respectively. Meiotic maturation and cumulus cell expansion significantly decreased for COCs after TCS treatment along with an increase in mitochondrial superoxide levels at 44 h of IVM. Further, mitochondrion-related antioxidant enzymes and apoptosis markers were significantly elevated in porcine COCs following TCS-mediated oxidative damage. The protective effect of Mito-TEMPO as a specific superoxide scavenger from TCS toxin improved the maturation capacity of porcine COCs. Mito-TEMPO downregulated the mitochondrial apoptosis of TCS-exposed porcine COCs by reducing superoxide level. In conclusion, our data demonstrate that TCS mediates toxicity during porcine oocyte maturation through superoxide production and mitochondrion-mediated apoptosis.


Asunto(s)
Oocitos/citología , Compuestos Organofosforados/farmacología , Piperidinas/toxicidad , Superóxidos/metabolismo , Triclosán/toxicidad , Animales , Apoptosis/efectos de los fármacos , Células del Cúmulo/citología , Células del Cúmulo/efectos de los fármacos , Células del Cúmulo/metabolismo , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Técnicas de Maduración In Vitro de los Oocitos , Mitocondrias/metabolismo , Oocitos/efectos de los fármacos , Oocitos/metabolismo , Compuestos Organofosforados/toxicidad , Estrés Oxidativo/efectos de los fármacos , Porcinos
19.
Angew Chem Int Ed Engl ; 59(26): 10645-10650, 2020 06 22.
Artículo en Inglés | MEDLINE | ID: mdl-32198805

RESUMEN

N6 -isopentenyladenosine (i6 A) is an RNA modification found in cytokinins, which regulate plant growth/differentiation, and a subset of tRNAs, where it improves the efficiency and accuracy of translation. The installation and removal of this modification is mediated by prenyltransferases and cytokinin oxidases, and a chemical approach to selective deprenylation of i6 A has not been developed. We show that a selected group of oxoammonium cations function as artificial deprenylases to promote highly selective deprenylation of i6 A in nucleosides, oligonucleotides, and live cells. Importantly, other epigenetic modifications, amino acid residues, and natural products were not affected. Moreover, a significant phenotype difference in the Arabidopsis thaliana shoot and root development was observed with incubation of the cation. These results establish these small organic molecules as direct chemical regulators/artificial deprenylases of i6 A.


Asunto(s)
Óxidos N-Cíclicos/farmacología , Citocininas/metabolismo , Isopenteniladenosina/metabolismo , Piperidinas/farmacología , Prenilación/efectos de los fármacos , ARN/metabolismo , Arabidopsis/efectos de los fármacos , Óxidos N-Cíclicos/química , Óxidos N-Cíclicos/toxicidad , Citocininas/química , Epigénesis Genética/efectos de los fármacos , Humanos , Isopenteniladenosina/química , Células MCF-7 , Oligorribonucleótidos/química , Oligorribonucleótidos/metabolismo , Piperidinas/química , Piperidinas/toxicidad , Reguladores del Crecimiento de las Plantas/química , Reguladores del Crecimiento de las Plantas/metabolismo , Raíces de Plantas/efectos de los fármacos , Brotes de la Planta/efectos de los fármacos , ARN/química
20.
Mol Carcinog ; 58(5): 722-734, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30582219

RESUMEN

Bioactive derivatives from the camphor laurel tree, Cinnamomum camphora, are posited to exhibit chemopreventive properties but the efficacy and mechanism of these natural products are not fully understood. We tested an essential-oil derivative, camphor white oil (CWO), for anti-tumor activity in a mouse model of keratinocyte-derived skin cancer. Daily topical treatment with CWO induced dramatic regression of pre-malignant skin tumors and a two-fold reduction in cutaneous squamous cell carcinomas. We next investigated underlying cellular and molecular mechanisms. In cultured keratinocytes, CWO stimulated calcium signaling, resulting in calcineurin-dependent activation of nuclear factor of activated T cells (NFAT). In vivo, CWO induced transcriptional changes in immune-related genes identified by RNA-sequencing, resulting in cytotoxic T cell-dependent tumor regression. Finally, we identified chemical constituents of CWO that recapitulated effects of the admixture. Together, these studies identify T cell-mediated tumor regression as a mechanism through which a plant-derived essential oil diminishes established tumor burden.


Asunto(s)
Alcanfor/administración & dosificación , Carcinoma de Células Escamosas/tratamiento farmacológico , Queratinocitos/efectos de los fármacos , Aceites Volátiles/administración & dosificación , Neoplasias Cutáneas/tratamiento farmacológico , Linfocitos T Citotóxicos/inmunología , Animales , Antracenos/toxicidad , Carcinoma de Células Escamosas/inducido químicamente , Carcinoma de Células Escamosas/inmunología , Proliferación Celular , Células Cultivadas , Femenino , Humanos , Queratinocitos/inmunología , Queratinocitos/patología , Ratones , Factores de Transcripción NFATC/metabolismo , Piperidinas/toxicidad , Neoplasias Cutáneas/inducido químicamente , Neoplasias Cutáneas/inmunología , Linfocitos T Citotóxicos/efectos de los fármacos , Linfocitos T Citotóxicos/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA